Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 88

1.

Pharmacists and Cardiologists in the ACC.

Kovacs RJ, Birtcher KK, Tisdale JE.

J Am Coll Cardiol. 2019 Jul 23;74(3):470-472. doi: 10.1016/j.jacc.2019.06.015. No abstract available.

PMID:
31319921
2.

Editorial commentary: Amiodarone-induced thyroid diseases: Additional unintended consequences.

Tisdale JE.

Trends Cardiovasc Med. 2019 Jul;29(5):296-297. doi: 10.1016/j.tcm.2018.10.003. Epub 2018 Oct 13. No abstract available.

PMID:
31130186
3.

Proarrhythmic food for thought.

Tisdale JE.

Heart Rhythm. 2019 Aug;16(8):1149-1150. doi: 10.1016/j.hrthm.2019.05.010. Epub 2019 May 15. No abstract available.

PMID:
31100489
4.

Progesterone pretreatment reduces the incidence of drug-induced torsades de pointes in atrioventricular node-ablated isolated perfused rabbit hearts.

Tisdale JE, Jaynes HA, Overholser BR, Sowinski KM, Kovacs RJ.

J Cardiovasc Electrophysiol. 2019 Jun;30(6):941-949. doi: 10.1111/jce.13942. Epub 2019 Apr 21.

PMID:
31006943
5.

Amiodarone for prevention of atrial fibrillation following esophagectomy.

Tisdale JE, Jaynes HA, Watson MR, Corya AL, Shen C, Kesler KA.

J Thorac Cardiovasc Surg. 2019 Jul;158(1):301-310.e1. doi: 10.1016/j.jtcvs.2019.01.095. Epub 2019 Feb 5.

PMID:
30853230
6.

Navigating the Minefield of QTc Interval-Prolonging Therapy in Nursing Facility Residents.

Zarowitz BJ, Tisdale JE.

J Am Geriatr Soc. 2019 Jul;67(7):1508-1515. doi: 10.1111/jgs.15810. Epub 2019 Feb 12. Review.

PMID:
30747995
7.

Predictive Analytics for Identification of Patients at Risk for QT Interval Prolongation: A Systematic Review.

Tomaselli Muensterman E, Tisdale JE.

Pharmacotherapy. 2018 Aug;38(8):813-821. doi: 10.1002/phar.2146. Epub 2018 Jul 18.

PMID:
29882591
8.

La recherche réalisée par les pharmaciens d’hôpitaux : une composante indispensable de la pratique quotidienne ou une attente irréaliste?

Tisdale JE.

Can J Hosp Pharm. 2018 Mar-Apr;71(2):97-98. Epub 2018 Apr 30. French. No abstract available.

PMID:
29736041
Free PMC Article
9.

Research Conducted by Hospital Pharmacists: Integral Component of Daily Practice or Unrealistic Expectation?

Tisdale JE.

Can J Hosp Pharm. 2018 Mar-Apr;71(2):95-96. Epub 2018 Apr 30. No abstract available.

10.

Ondansetron blocks wild-type and p.F503L variant small-conductance Ca2+-activated K+ channels.

Ko JS, Guo S, Hassel J, Celestino-Soper P, Lynnes TC, Tisdale JE, Zheng JJ, Taylor SE, Foroud T, Murray MD, Kovacs RJ, Li X, Lin SF, Chen Z, Vatta M, Chen PS, Rubart M.

Am J Physiol Heart Circ Physiol. 2018 Aug 1;315(2):H375-H388. doi: 10.1152/ajpheart.00479.2017. Epub 2018 Apr 20.

11.

Editorial Commentary: Optimization of dose selection for nonvitamin K antagonist oral anticoagulants.

Tisdale JE.

Trends Cardiovasc Med. 2017 Nov;27(8):573-574. doi: 10.1016/j.tcm.2017.06.015. Epub 2017 Jun 30. No abstract available.

PMID:
28709810
12.

Contribution of medications and risk factors to QTc interval lengthening in the atherosclerosis risk in communities (ARIC) study.

Alburikan KA, Aldemerdash A, Savitz ST, Tisdale JE, Whitsel EA, Soliman EZ, Thudium EM, Sueta CA, Kucharska-Newton AM, Stearns SC, Rodgers JE.

J Eval Clin Pract. 2017 Dec;23(6):1274-1280. doi: 10.1111/jep.12776. Epub 2017 Jul 10.

13.

Influence of Oral Progesterone Administration on Drug-Induced QT Interval Lengthening: A Randomized, Double-Blind, Placebo-Controlled Crossover Study.

Tisdale JE, Jaynes HA, Overholser BR, Sowinski KM, Flockhart DA, Kovacs RJ.

JACC Clin Electrophysiol. 2016 Dec;2(7):765-774. doi: 10.1016/j.jacep.2016.02.015.

14.

Prevalence and significance of acquired QT interval prolongation in hospitalized patients.

Tisdale JE.

Heart Rhythm. 2017 Jul;14(7):979-980. doi: 10.1016/j.hrthm.2017.03.036. Epub 2017 Mar 30. No abstract available.

PMID:
28366778
15.

Iterative Development and Evaluation of a Pharmacogenomic-Guided Clinical Decision Support System for Warfarin Dosing.

Melton BL, Zillich AJ, Saleem J, Russ AL, Tisdale JE, Overholser BR.

Appl Clin Inform. 2016 Nov 23;7(4):1088-1106.

16.

Allongement de l'intervalle QT causé par des médicaments chez l'enfant : comment vont les enfants?

Tisdale JE.

Can J Hosp Pharm. 2016 May-Jun;69(3):185-6. Epub 2016 Jun 30. French. No abstract available.

17.

Drug-Induced QT Interval Prolongation in Children: Are the Kids Alright?

Tisdale JE.

Can J Hosp Pharm. 2016 May-Jun;69(3):183-4. Epub 2016 Jun 30. No abstract available.

18.

Efavirenz Inhibits the Human Ether-A-Go-Go Related Current (hERG) and Induces QT Interval Prolongation in CYP2B6*6*6 Allele Carriers.

Abdelhady AM, Shugg T, Thong N, Lu JB, Kreutz Y, Jaynes HA, Robarge JD, Tisdale JE, Desta Z, Overholser BR.

J Cardiovasc Electrophysiol. 2016 Oct;27(10):1206-1213. doi: 10.1111/jce.13032. Epub 2016 Jul 25.

19.

Drug-induced QT interval prolongation and torsades de pointes: Role of the pharmacist in risk assessment, prevention and management.

Tisdale JE.

Can Pharm J (Ott). 2016 May;149(3):139-52. doi: 10.1177/1715163516641136. Epub 2016 Apr 8. Review.

20.

Influence of Zoledronic Acid on Atrial Electrophysiological Parameters and Electrocardiographic Measurements.

Tisdale JE, Allen MR, Overholser BR, Jaynes HA, Kovacs RJ.

J Cardiovasc Electrophysiol. 2015 Jun;26(6):671-7. doi: 10.1111/jce.12641. Epub 2015 Mar 31.

21.

2014 AATS guidelines for the prevention and management of perioperative atrial fibrillation and flutter for thoracic surgical procedures.

Frendl G, Sodickson AC, Chung MK, Waldo AL, Gersh BJ, Tisdale JE, Calkins H, Aranki S, Kaneko T, Cassivi S, Smith SC Jr, Darbar D, Wee JO, Waddell TK, Amar D, Adler D; American Association for Thoracic Surgery.

J Thorac Cardiovasc Surg. 2014 Sep;148(3):e153-93. doi: 10.1016/j.jtcvs.2014.06.036. Epub 2014 Jun 30. Review. No abstract available.

22.

2014 AATS guidelines for the prevention and management of perioperative atrial fibrillation and flutter for thoracic surgical procedures. Executive summary.

Frendl G, Sodickson AC, Chung MK, Waldo AL, Gersh BJ, Tisdale JE, Calkins H, Aranki S, Kaneko T, Cassivi S, Smith SC Jr, Darbar D, Wee JO, Waddell TK, Amar D, Adler D; American Association of Thoracic Surgery.

J Thorac Cardiovasc Surg. 2014 Sep;148(3):772-91. doi: 10.1016/j.jtcvs.2014.06.037. Epub 2014 Jun 28. Review. No abstract available.

23.

What causes some patients with drug-induced QT interval prolongation to develop torsades de pointes but not others? The elusive missing link.

Tisdale JE.

Drugs Aging. 2014 Aug;31(8):577-9. doi: 10.1007/s40266-014-0199-8. No abstract available.

PMID:
25023065
24.

Pourrais-je avoir des lignes directrices pour m'aider à interpréter les lignes directrices thérapeutiques?

Tisdale JE.

Can J Hosp Pharm. 2014 May;67(3):186-7. French. No abstract available.

25.

Can I get a guideline to help me interpret treatment guidelines?

Tisdale JE.

Can J Hosp Pharm. 2014 May;67(3):181-2. No abstract available.

26.

Effectiveness of a clinical decision support system for reducing the risk of QT interval prolongation in hospitalized patients.

Tisdale JE, Jaynes HA, Kingery JR, Overholser BR, Mourad NA, Trujillo TN, Kovacs RJ.

Circ Cardiovasc Qual Outcomes. 2014 May;7(3):381-90. doi: 10.1161/CIRCOUTCOMES.113.000651. Epub 2014 May 6. Erratum in: Circ Cardiovasc Qual Outcomes. 2014 Nov;7(6):981.

27.

QT interval prolongation and the risk of torsades de pointes: essentials for clinicians.

Trinkley KE, Page RL 2nd, Lien H, Yamanouye K, Tisdale JE.

Curr Med Res Opin. 2013 Dec;29(12):1719-26. doi: 10.1185/03007995.2013.840568. Epub 2013 Sep 23. Review.

PMID:
24020938
28.

Development and validation of a risk score to predict QT interval prolongation in hospitalized patients.

Tisdale JE, Jaynes HA, Kingery JR, Mourad NA, Trujillo TN, Overholser BR, Kovacs RJ.

Circ Cardiovasc Qual Outcomes. 2013 Jul;6(4):479-87. doi: 10.1161/CIRCOUTCOMES.113.000152. Epub 2013 May 28. Erratum in: Circ Cardiovasc Qual Outcomes. 2013 Nov;6(6):e57.

29.

Pharmacokinetic modeling and simulation of procainamide and N-acetylprocainamide in a patient receiving continuous renal replacement therapy: a novel approach to guide renal dose adjustments.

Mohamed AN, Abdelhady AM, Spencer D, Sowinski KM, Tisdale JE, Overholser BR.

Am J Kidney Dis. 2013 Jun;61(6):1046-8. doi: 10.1053/j.ajkd.2013.02.358. Epub 2013 Apr 4. No abstract available.

30.

Hospital pharmacy in Canada: ahead of the curve.

Tisdale JE, Hall KW.

Can J Hosp Pharm. 2012 Sep;65(5):345-50. English, French. No abstract available.

31.

Experiential training for pharmacy students: time for a new approach.

Hall K, Musing E, Miller DA, Tisdale JE.

Can J Hosp Pharm. 2012 Jul;65(4):285-93. No abstract available.

32.

Drug-induced atrial fibrillation.

Kaakeh Y, Overholser BR, Lopshire JC, Tisdale JE.

Drugs. 2012 Aug 20;72(12):1617-30. doi: 10.2165/11633140-000000000-00000. Review.

33.

High risk of QT interval prolongation and torsades de pointes associated with intravenous quinidine used for treatment of resistant malaria or babesiosis.

Wroblewski HA, Kovacs RJ, Kingery JR, Overholser BR, Tisdale JE.

Antimicrob Agents Chemother. 2012 Aug;56(8):4495-9. doi: 10.1128/AAC.06396-11. Epub 2012 May 21.

34.
35.

Toward a unified model for contemporary institutional pharmacy practice.

Tisdale JE.

Can J Hosp Pharm. 2011 Mar;64(2):97-103. English, French. No abstract available.

36.

Enhanced sensitivity to drug-induced QT interval lengthening in patients with heart failure due to left ventricular systolic dysfunction.

Tisdale JE, Overholser BR, Wroblewski HA, Sowinski KM, Amankwa K, Borzak S, Kingery JR, Coram R, Zipes DP, Flockhart DA, Kovacs RJ.

J Clin Pharmacol. 2012 Sep;52(9):1296-305. doi: 10.1177/0091270011416939. Epub 2011 Nov 1.

37.

The Society of Thoracic Surgeons practice guideline on the prophylaxis and management of atrial fibrillation associated with general thoracic surgery: executive summary.

Fernando HC, Jaklitsch MT, Walsh GL, Tisdale JE, Bridges CD, Mitchell JD, Shrager JB.

Ann Thorac Surg. 2011 Sep;92(3):1144-52. doi: 10.1016/j.athoracsur.2011.06.104. Review. No abstract available.

PMID:
21871327
38.

The influence of progesterone alone and in combination with estradiol on ventricular action potential duration and triangulation in response to potassium channel inhibition.

Tisdale JE, Overholser BR, Wroblewski HA, Sowinski KM.

J Cardiovasc Electrophysiol. 2011 Mar;22(3):325-31. doi: 10.1111/j.1540-8167.2010.01869.x. Epub 2010 Aug 19.

PMID:
20731743
39.

A randomized, controlled study of amiodarone for prevention of atrial fibrillation after transthoracic esophagectomy.

Tisdale JE, Wroblewski HA, Wall DS, Rieger KM, Hammoud ZT, Young JV, Kesler KA.

J Thorac Cardiovasc Surg. 2010 Jul;140(1):45-51. doi: 10.1016/j.jtcvs.2010.01.026. Epub 2010 Apr 9.

40.

Prophylaxis of atrial fibrillation after noncardiac thoracic surgery.

Tisdale JE, Wroblewski HA, Kesler KA.

Semin Thorac Cardiovasc Surg. 2010 Winter;22(4):310-20. doi: 10.1053/j.semtcvs.2010.12.001. Review.

PMID:
21549271
41.

Integrity in authorship and publication.

Tisdale JE.

Can J Hosp Pharm. 2009 Nov;62(6):441-7. English, French. No abstract available.

42.

A randomized trial evaluating amiodarone for prevention of atrial fibrillation after pulmonary resection.

Tisdale JE, Wroblewski HA, Wall DS, Rieger KM, Hammoud ZT, Young JV, Kesler KA.

Ann Thorac Surg. 2009 Sep;88(3):886-93; discussion 894-5. doi: 10.1016/j.athoracsur.2009.04.074.

PMID:
19699916
43.

Paroxysmal beta-adrenergic receptor-mediated alterations in ventricular repolarization at rapid heart rates during inhibition of delayed rectifier currents.

Overholser BR, Zheng X, Tisdale JE.

J Cardiovasc Pharmacol. 2009 Sep;54(3):253-62. doi: 10.1097/FJC.0b013e3181b2b706.

PMID:
19620881
44.

APhA2009 House of Delegates: serving the association and the profession.

Weitzel KW, Tisdale JE, Mattingly J.

J Am Pharm Assoc (2003). 2009 Jul-Aug;49(4):474-80. doi: 10.1331/JAPhA.2009.09520. No abstract available.

PMID:
19589755
45.

Pharmacokinetics of ibutilide in patients with heart failure due to left ventricular systolic dysfunction.

Tisdale JE, Overholser BR, Sowinski KM, Wroblewski HA, Amankwa K, Borzak S, Kingery JR, Coram R, Zipes DP, Flockhart DA, Kovacs RJ.

Pharmacotherapy. 2008 Dec;28(12):1461-70. doi: 10.1592/phco.28.12.1461.

PMID:
19025427
46.

Catecholaminergic effects on ventricular repolarization during inhibition of the rapid component of the delayed rectifier potassium current in a perfused heart model.

Overholser BR, Zheng X, Tisdale JE.

Pharmacotherapy. 2008 Nov;28(11):1315-24. doi: 10.1592/phco.28.11.1315.

PMID:
18956991
47.

Effect of drugs on defibrillation capacity.

Dopp AL, Miller JM, Tisdale JE.

Drugs. 2008;68(5):607-30. Review.

PMID:
18370441
48.

Prospective evaluation of serum amiodarone concentrations when administered via a nasogastric tube into the stomach conduit after transthoracic esophagectomy.

Tisdale JE, Wroblewski HA, Hammoud ZT, Rieger KM, Young JV, Wall DS, Kesler KA.

Clin Ther. 2007 Oct;29(10):2226-34.

PMID:
18042479
49.

Amiodarone prophylaxis for atrial fibrillation after cardiac surgery: meta-analysis of dose response and timing of initiation.

Buckley MS, Nolan PE Jr, Slack MK, Tisdale JE, Hilleman DE, Copeland JG.

Pharmacotherapy. 2007 Mar;27(3):360-8.

PMID:
17316148
50.

Accuracy of uncorrected versus corrected QT interval for prediction of torsade de pointes associated with intravenous haloperidol.

Tisdale JE, Kovacs R, Mi D, McCabe GP, Cariera BL, Sharma N, Rosman H.

Pharmacotherapy. 2007 Feb;27(2):175-82.

PMID:
17253907

Supplemental Content

Loading ...
Support Center